TrialNature communications2026

Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.

Jeffrey S Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.